Clinical Data from Phase 1 DoseEscalation Study of SingleAgent NKTR214 in Patients with Renal Cell Carcinoma Presented at the ASCO 2017 Genitourinary Cancers Symposium

SAN FRANCISCO and ORLANDO Fla. Feb. 18 2017 PRNewswire Nektar Therapeutics Nasdaq NKTR today announced that positive Phase 1 clinical data for Nektar's lead immunooncology agent NKTR214 in patients with renal cell carcinoma RCC were presented at ASCO GU 2...